Pfiz­er con­sid­ers an­tivi­ral op­tions as Paxlovid use sky­rock­ets amid wor­ries of re­sis­tance

When Pfiz­er’s Covid-19 an­tivi­ral Paxlovid first hit the shelves last De­cem­ber, it was wide­ly seen as the best op­tion to keep those at high risk of hos­pi­tal­iza­tion out of the hos­pi­tal.

But that ear­ly cau­tion with re­gard to who re­ceived the pill has gen­er­al­ly been thrown in­to the wind as al­most a mil­lion Amer­i­cans per month (or about 1 in every 4 of­fi­cial­ly re­port­ed Covid-19 case) now us­es the an­tivi­ral, ac­cord­ing to the lat­est US gov­ern­ment da­ta. The spike in us­age comes as phar­ma­cists are now al­lowed to of­fer Paxlovid in the US, and as Pfiz­er be­gins to weigh its op­tions with re­gard to com­bo treat­ments and a sec­ond-gen­er­a­tion an­tivi­ral.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.